Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7338874 | 0.93 | MCL1 (0.47) | NPC1RAB9ASMN1; SMN2AGTR2POLB | |
| SCHEMBL7338869 | 0.93 | MCL1 (0.47) | NPC1RAB9ASMN1; SMN2AGTR2POLB | |
| SCHEMBL7346785 | 0.92 | AGTR2 (0.46) | NPC1RAB9ASMN1; SMN2AGTR2POLB | |
| SCHEMBL9570543 | 0.89 | LMNA (0.46) | — | |
| SCHEMBL9570545 | 0.89 | LMNA (0.46) | — | |
| SCHEMBL7342091 | 0.89 | BDKRB2 (0.45) | NPC1RAB9ASMN1; SMN2AGTR2POLB | |
| SCHEMBL7342093 | 0.89 | BDKRB2 (0.45) | NPC1RAB9ASMN1; SMN2AGTR2POLB | |
| SCHEMBL7015458 | 0.88 | POLB (0.47) | NPC1RAB9ASMN1; SMN2POLBHTR2C | |
| SCHEMBL2298566 | 0.88 | POLB (0.47) | NPC1RAB9ASMN1; SMN2POLBHTR2C | |
| SCHEMBL7015459 | 0.88 | POLB (0.47) | NPC1RAB9ASMN1; SMN2POLBHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8378099-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACUETICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-8003791-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-0788360-B3 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARM INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7531526-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1997823-A1 | Boronic ester and acid compounds, synthesis and uses | Millennium Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1627880-B1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARM INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-6548668-B2 | Stabilizer for proteins | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020173488-A1 | Boronic Ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | US | disclosed |
| US-6465433-B1 | SUCH AS N-(2-PYRIDINE)CARBONYL-L-PHENYLALANINE-L-LEUCINE BORONIC ACID; PROTEASOME INHIBITORS; REDUCING RATE OF MUSCLE PROTEIN DEGRADATION | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6297217-B1 | TREATMENT OF CANCER WITH PROTEASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6083903-A | REDUCE RATE OF DEGRADATION OF PROTEINS IN ANIMAL | LEUKOSITE, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-6066730-A | Boronic ester and acid compounds, synthesis and uses | PROSCRIPT, INC. | 2000-05-23 | — | — | US | disclosed |
| US-5780454-A | Boronic ester and acid compounds | PROSCRIPT, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0788360-A4 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0788360-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | NPC1 561/4885RAB9A 692/4885SMN1; SMN2 960/4885 |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | NPC1 561/4885RAB9A 692/4885SMN1; SMN2 960/4885 |
| US-20020173488-A1 | Boronic Ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | NPC1 737/4885RAB9A 602/4885SMN1; SMN2 858/4885 |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | NPC1 561/4885RAB9A 692/4885SMN1; SMN2 960/4885 |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | NPC1 561/4885RAB9A 692/4885SMN1; SMN2 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.